EPS Revision Bonanza: LILA +61%, HELP +47%, BDSX +42% Lead Surge
The EPS revision screener detected massive upward estimate changes in LILA and LILAK, which subsequently rallied 61% and 59%, respectively, with no news catalysts. HELP gained 47% after its EPS estimate was raised and was further boosted by positive fiscal 2026 results. BDSX and QNRX also advanced 41-40% on modest but well-received revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| LILA | Communication Services | 2026-06-18 | +131.8pp | +61.0% |
| LILAK | Communication Services | 2026-06-18 | +1799.9pp | +59.3% |
| HELP | Healthcare | 2026-06-21 | N/A | +47.3% |
| BDSX | Healthcare | 2026-06-18 | +2.5pp | +41.6% |
| QNRX | Healthcare | 2026-06-23 | +9.5pp | +40.0% |
Why did LILA stock jump in June 2026?
LILA jumped 61.0% (from $4.80 to $7.73) after analysts raised its forward EPS growth estimate from 208.4% to 340.3% on June 18.
The revision reflects sharply improving earnings expectations for the communication services company, likely tied to broader Latin American telecom recovery. No specific company news broke during the period, suggesting the price move was driven entirely by the EPS upgrade and subsequent momentum from the screener detection.
LILA EPS revision history → · Screener snapshot from 2026-06-18 →
FAQ: LILA
Why did LILA stock jump in June 2026?
LILA surged 61% after analysts boosted its next-year EPS growth estimate from 208.4% to 340.3% on June 18, with no other major news.
Is LILA a buy after the rally?
The massive EPS revision suggests strong earnings momentum, but investors should consider the sustainability of the telecom recovery in Latin America.
What is LILA's EPS growth estimate?
LILA's next-year EPS growth estimate was raised to 340.3% from 208.4% as of June 18, 2026.
Why did LILAK stock jump in June 2026?
LILAK jumped 59.3% (from $4.79 to $7.63) after analysts raised its forward EPS growth estimate from 413.6% to 2,213.6% on June 18.
The revision represents an extraordinary turnaround expectation for the Class A shares of Liberty Latin America, with EPS growth projected to soar. Like its counterpart LILA, the move occurred without company-specific news, driven entirely by the earnings estimate upgrade and sector-wide enthusiasm.
LILAK EPS revision history → · Screener snapshot from 2026-06-18 →
FAQ: LILAK
Why did LILAK stock surge in June 2026?
LILAK jumped 59% after its next-year EPS growth estimate was raised from 413.6% to 2,213.6% on June 18, with no accompanying news.
Is LILAK a buy after the rally?
The extreme EPS revision implies very high earnings growth expectations, but such projections carry significant execution risk.
What caused LILAK's price to rise?
The primary driver was the upward EPS revision of +1,799.9 percentage points detected by the screener, reflecting suddenly higher profit forecasts.
Why did HELP stock jump in June 2026?
HELP jumped 47.3% (from $4.67 to $6.88) after analysts revised its next-year EPS growth estimate upward to 27.7% on June 21, reinforced by strong fiscal 2026 results.
The company reported fiscal year 2026 financial results on June 29, highlighting 88% enrollment in its Phase 3 APPROACH study for MDD and a $50 million underwritten offering. The combination of the EPS upgrade and positive clinical milestones drove the stock sharply higher.
HELP EPS revision history → · Screener snapshot from 2026-06-21 →
FAQ: HELP
Why did HELP stock jump in June 2026?
HELP rose 47% after its next-year EPS growth estimate was revised to 27.7% and the company reported strong fiscal 2026 results with 88% enrollment in its Phase 3 MDD study.
Is HELP a buy after the rally?
The positive clinical progress and EPS upgrade suggest momentum, but the stock still faces binary risk from Phase 3 topline data expected in Q4 2026.
What did HELP's fiscal 2026 results show?
HELP reported a $50 million underwritten offering, 88% enrollment in its Phase 3 APPROACH study for MDD, and 100% response rate in Phase 2 data at 12 months.
Why did BDSX stock jump in June 2026?
BDSX jumped 41.6% (from $16.81 to $23.81) after analysts raised its forward EPS growth estimate from 38.2% to 40.7% on June 18.
While the revision was modest (+2.5pp), the market reacted strongly, likely due to Biodesix's position in the diagnostic testing sector gaining momentum. No company-specific news emerged, suggesting the move was driven by the earnings estimate upgrade and sector flows.
BDSX EPS revision history → · Screener snapshot from 2026-06-18 →
FAQ: BDSX
Why did BDSX stock rally in June 2026?
BDSX rose 42% after its next-year EPS growth estimate was raised from 38.2% to 40.7% on June 18, with no other earnings-related news.
Is BDSX a buy after the rally?
The EPS revision is modest, but the strong price action suggests the market is pricing in continued improvement in the diagnostic sector.
What is BDSX's EPS growth estimate?
Biodesix's next-year EPS growth estimate was revised to 40.7% from 38.2% as of June 18, 2026.
Why did QNRX stock jump in June 2026?
QNRX jumped 40.0% (from $3.25 to $4.55) after analysts raised its forward EPS growth estimate from 45.4% to 54.8% on June 23.
The +9.5pp revision signals improving profitability expectations for Quoin Pharmaceuticals, a specialty pharmaceutical company. The surge occurred without earnings-related news, indicating the estimate revision itself acted as the catalyst.
QNRX EPS revision history → · Screener snapshot from 2026-06-23 →
FAQ: QNRX
Why did QNRX stock jump in June 2026?
QNRX gained 40% after its next-year EPS growth estimate was raised from 45.4% to 54.8% on June 23, with no company news.
Is QNRX a buy after the rally?
The upward revision supports a bullish outlook, but investors should monitor whether the company can deliver on the higher expectations.
What caused QNRX's surge?
The surge was triggered by the +9.5 percentage point upward revision in EPS growth estimates detected by the screener.
Today's top performers highlight that substantial earnings estimate revisions, even in the absence of company news, can drive significant price momentum, while clinical-stage healthcare names like HELP benefit from a combination of upgrades and operational milestones.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →